FDA OKS COVID SHOTS FOR INFANTS AND PRESCHOOLERS
Pfizer, Moderna both given backing; CDC weighing approval
U.S. regulators on Friday authorized the first COVID-19 shots for infants and preschoolers, paving the way for vaccinations to begin next week.
The Food and Drug Administration’s action follows its advisory panel’s unanimous recommendation for the shots from Moderna and Pfizer. That means U.S. kids younger than 5 — roughly 18 million youngsters — are eligible for the shots. The nation’s vaccination campaign began about 1 1⁄2 years ago with older adults, the hardest hit during the coronavirus pandemic.
There’s one step left: The
Centers for Disease Control and Prevention recommends how to use vaccines. Its independent advisers began debating the two-dose Moderna and the three-dose Pfizer vaccines on Friday and will make its recommendation today. A final sign-off is expected soon after from CDC Director Dr. Rochelle Walensky.
At a Senate hearing Thursday, Walensky said her staff was working over the Juneteenth federal holiday weekend “because we understand the urgency of this for American parents.”
She said pediatric deaths from COVID-19 have been higher than what is generally seen from the flu each year.
“So I actually think we need to protect young children, as well as protect everyone with the vaccine and especially protect elders,” she said.
The FDA also authorized Moderna’s vaccines for school-age children and teens; the CDC’s review is next week. Pfizer’s shots had been the only option for those age groups.
For weeks, the Biden administration has been preparing to roll out the vaccines for little kids, with states, tribes, community health centers and pharmacies preordering millions of doses. With the FDA’s emergency use authorization, manufacturers can begin shipping vaccines across the country. The shots are expected to start early next week but it’s not clear how popular they will be.
Without protection for their tots, some families had put off birthday parties, vacations and visits with grandparents.
“Today is a day of huge relief for parents and families across America,” President Joe Biden said in a statement.
While young children generally don’t get as sick from COVID-19 as older kids and adults, their hospitalizations surged during the Omicron wave and FDA’s advisers determined that benefits from vaccination outweighed the minimal risks. Studies from Moderna and Pfizer showed side effects, including fever and fatigue, were mostly minor.
White House COVID-19 coordinator Dr. Ashish Jha predicted the pace of vaccinations for kids under 5 to be far slower than it was for older populations and said the administration doesn’t have any internal targets for the pace of vaccinations.
“At the end of the day, our goal is very clear: We want to get as many kids vaccinated as possible,“Jha told The
Associated Press.
In testing, the youngest children developed high levels of virus-fighting antibodies, comparable to what is seen in young adults, the FDA said. Moderna’s vaccine was about 40 to 50 percent effective at preventing infections but there were too few cases during Pfizer’s study to give a reliable, exact estimate of effectiveness, the agency said.
“Both of these vaccines have been authorized with science and safety at the forefront of our minds,” Dr. Peter Marks, FDA’s vaccine chief, said at a news briefing.
Marks said parents should feel comfortable with either vaccine, and should get their kids vaccinated as soon as possible, rather than waiting until fall, when a different virus variant might be circulating. He said adjustments in the vaccines would be made to account for that.
“Whatever vaccine your health care provider, pediatrician has, that’s what I would give my child,” Marks said.
The two brands use the same technology but there are differences.
Pfizer’s vaccine for kids younger than 5 is one-tenth of the adult dose. Three shots are needed: the first two given three weeks apart and the last at least two months later.
Moderna’s is two shots, each a quarter of its adult dose, given about four weeks apart for kids under 6. The FDA also authorized a third dose, at least a month after the second shot, for children who have immune conditions that make them more vulnerable to serious illness.